Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age - Halperin, Scott A.; Ward, Brian; Cooper, Curtis; Predy, Gerald; Diaz-Mitoma, Francisco; Dionne, Marc; Embree, Joanne; McGeer, Allison; Zickler, Paul; Moltz, Karl-Heinz; Martz, René; Meyer, Ingo; et al. (Vaccine, 2012)
Keywords: Adjuvants, Immunologic; Adolescent; Adult; adults; Age; Allergy and Immunology; Antibody response; Antigens; Autoimmune diseases; Chronic illnesses; Female; Hepatitis; hepatitis B; Hepatitis B - prevention & control; Hepatitis B Antibodies - immunology; hepatitis B antigens; Hepatitis B surface antigen; Hepatitis B Surface Antigens - administration & dosage; Hepatitis B Surface Antigens - adverse effects; Hepatitis B Surface Antigens - immunology; Hepatitis B vaccine; Hepatitis B Vaccines - administration & dosage; Hepatitis B Vaccines - adverse effects; Hepatitis B Vaccines - immunology; Hepatitis B virus; Hepatitis B virus - immunology; Humans; Immune response; Immunogenicity; Immunostimulation; Immunostimulatory sequences; Infections; injection site; Licenses; Liver cancer; Male; Middle Aged; Oligodeoxyribonucleotides - administration & dosage; Oligodeoxyribonucleotides - adverse effects; Oligodeoxyribonucleotides - immunology; Oligonucleotides; phosphorothioate; Randomized trial; surface antigens; Teenagers; Vaccines; Young Adult; Hepatitis B vaccine; Randomized trial; Immunostimulatory sequences